in preclinical models it activates the VEGFR2-Akt-eNOS signaling axis to promote angiogenesis and tissue vascularization ( It also engages ERK1/2 and FAK-paxillin pathways that regulate endothelial cell migration and fibroblast activity, and upregulates heat shock proteins (HSP70/90) for cytoprotective effects in gastrointestinal tissue models ( Research across multiple rodent injury models has characterized its activity in tendon, muscle, nerve, and GI tissue contexts

New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
Theres also the not-so-quiet rise of fiber
They include carbidopa/levodopa (Sinemet), pramipexole (Mirapex), ropinirole (Requip) and the rotigotine patch (Neupro)
Secondary Aging: Untangling the Threads of Time pH Levels, Cancer, and Weight Loss
Final Thoughts Semaglutide and tirzepatide both regulate appetite and blood sugar, but their distinct receptor mechanisms may lead to different outcomes based on individual health goals